

## Abbvie's Jak measures up nicely in eczema



[Elizabeth Cairns](#)


Phase III results toplined yesterday suggest that Abbvie's Jak inhibitor Rinvoq might be the most efficacious atopic dermatitis therapy in late-stage trials. Moderate to severe eczema patients receiving 15mg or 30mg of Rinvoq monotherapy in the [Measure Up 1 trial](#) showed statistically significantly better skin clearance than those given placebo. A cross-trial comparison of Rinvoq's scores on the study's co-primary endpoints – a minimum 75% improvement in the eczema area severity index (EASI 75) and a validated investigator's global assessment (IGA) for atopic dermatitis of 0 or 1, representing clear or almost clear skin – show it surpassing Pfizer's Jak, abrocitinib, in its phase III trials. It also easily beats Sanofi/Regeneron's market leader, Dupixent. As with all Jaks safety is key, and here the news is cheering for Abbvie, with the rate of serious adverse events identical in the high-dose and placebo groups. Less than 1% of Rinvoq patients had serious infections versus none on placebo, and there were no deaths, venous thromboemboli or major cardiac events. If the several other ongoing phase III eczema trials post similarly decent data, Rinvoq could find a niche as second-line, post-Dupixent, therapy.

### Rinvoq's phase III trials in moderate to severe eczema

Trial details	N	PCD	Trial ID
Monotherapy, vs placebo (Measure Up 1)	810	Jan 2021	<a href="#">NCT03569293</a>
Monotherapy, vs placebo (Measure Up 2)	810	Jan 2021	<a href="#">NCT03607422</a>
Monotherapy, vs Dupixent and placebo (Heads Up)	692	Sep 2020	<a href="#">NCT03738397</a>
Open-label extension to Heads Up	600	Jul 2021	<a href="#">NCT04195698</a>
Combo w topical corticosteroids, vs placebo	272	Feb 2022	<a href="#">NCT03661138</a>
Combo w topical corticosteroids, vs placebo (AD Up)	810	Aug 2022	<a href="#">NCT03568318</a>

PCD=Primary completion date. Source: EvaluatePharma.

# Cross-trial comparison of phase III eczema data



- Rinvoq 15mg daily (Measure Up 1)
- Rinvoq 30mg daily (Measure Up 1)
- Abrocitinib 200mg daily (Jade-Mono-1)
- Abrocitinib 200mg daily (Jade-Mono-2)
- Dupixent 300mg q 2wk (Solo-1)
- Dupixent 300mg q 2wk (Solo-2)

Week 12. Selected doses. Source: company releases; clinicaltrials.gov; EvaluatePharma.